BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin S, Wang Q, Wu H, Pang D, Xu S. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res 2021;9:71. [PMID: 34563270 DOI: 10.1186/s40364-021-00318-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Wen Z, Chen H, Yang Z, Le Z, Liu Z, Chen Y, Liu L. Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. Journal of Controlled Release 2022;352:497-506. [DOI: 10.1016/j.jconrel.2022.10.053] [Reference Citation Analysis]
2 Hooda-nehra A, L. Smith T, I. Ferrer A, I. Staquicini F, Arap W, Pasqualini R, Rameshwar P. Targeted Regulation and Cellular Imaging of Tumor-Associated Macrophages in Triple-Negative Breast Cancer: From New Mechanistic Insights to Candidate Translational Applications. Macrophages celebrating 140 years of discovery [Working Title] 2022. [DOI: 10.5772/intechopen.105654] [Reference Citation Analysis]
3 Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol 2021;11:803050. [PMID: 35004328 DOI: 10.3389/fonc.2021.803050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]